Sanofi a beneficiary of Alnylam’s data on heart drug Amvuttra
2024-06-24
RomanBabakin Sanofi (NASDAQ:SNY) is up ~3% in Monday afternoon trading as it stands to benefit from positive data released earlier in the day on Alnylam Pharmaceuticals’ (ALNY) Amvuttra (vutrisiran) The data was on the drug in treating ATTR amyloidosis with cardiomyopathy. The therapoy was already approved for polyneuropathy of hereditaryContinue Reading